Myeloid differentiation factor 88-independent Toll-like receptor pathway: Sustaining inflammation or promoting tolerance?

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 9, 2007, Pages 1582-1592

  Biswas, Subhra K ^a,b   Tergaonkar, Vinay ^c  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Endotoxin tolerance; MyD88; Toll like receptor; Trif

Indexed keywords

ENDOTOXIN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3;

CELL SURFACE; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PROTEIN FUNCTION; REACTOR CASCADE; SHORT SURVEY;

ANIMALS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

NEGIBACTERIA;

EID: 34547093419     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.04.021     Document Type: Short Survey

References (37)

1. Adib-Conquy M., and Cavaillon J.M. Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J. Biol. Chem. 277 (2002) 27927-27934
2. Akashi-Takamura S., and Miyake K. Toll-like receptors and immune disorders. J. Infect. Chemother. 12 (2006) 233-240
3. Anderson R.N., and Smith B.L. Deaths: Leading causes for 2002. Natl. Vital Stat. Rep. 53 (2005) 1-89
4. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430 (2004) 257-263
5. Beutler B. SHIP, TGF-beta, and endotoxin tolerance. Immunity 21 (2004) 134-135
6. Beutler B., and Rehli M. Evolution of the TIR, tolls and TLRs: Functional inferences from computational biology. Curr. Top. Microbiol. Immunol. 270 (2002) 1-21
7. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107 (2006) 2112-2122
8. Calvano J.E., Agnese D.M., Um J.Y., Goshima M., Singhal R., Coyle S.M., et al. Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, MD-2) and toll-like receptor 2 in systemic inflammatory response syndrome-positive patients with and without infection: Relationship to tolerance. Shock 20 (2003) 415-419
9. Cavaillon J.M., Adrie C., Fitting C., and Adib-Conquy M. Endotoxin tolerance: Is there a clinical relevance?. J. Endotoxin Res. 9 (2003) 101-107
10. Covert M.W., Leung T.H., Gaston J.E., and Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 309 (2005) 1854-1857
11. Cusson-Hermance N., Khurana S., Lee T.H., Fitzgerald K.A., and Kelliher M.A. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J. Biol. Chem. 280 (2005) 36560-36566
12. del Fresno C., Otero K., Gomez-Garcia L., Gonzalez-Leon M.C., Soler-Ranger L., Fuentes-Prior P., et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J. Immunol. 174 (2005) 3032-3040
13. Dobrovolskaia M.A., and Vogel S.N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 4 (2002) 903-914
14. Escoll P., del Fresno C., Garcia L., Valles G., Lendinez M.J., Arnalich F., et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem. Biophys. Res. Commun. 311 (2003) 465-472
15. Fan H., and Cook J.A. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10 (2004) 71-84
16. Hacker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L.C., Wang G.G., et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439 (2006) 204-207
17. Kaiser W.J., and Offermann M.K. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J. Immunol. 174 (2005) 4942-4952
18. Kawai T., Adachi O., Ogawa T., Takeda K., and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11 (1999) 115-122
19. Kawai T., and Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17 (2005) 338-344
20. Kawai T., and Akira S. Toll-like receptor downstream signaling. Arthritis Res. Ther. 7 (2005) 12-19
21. Kawai T., Takeuchi O., Fujita T., Inoue J., Muhlradt P.F., Sato S., et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167 (2001) 5887-5894
22. Kawasaki T., Ogata M., Kawasaki C., Tomihisa T., Okamoto K., and Shigematsu A. Surgical stress induces endotoxin hyporesponsiveness and an early decrease of monocyte mCD14 and HLA-DR expression during surgery. Anesth. Analg. 92 (2001) 1322-1326
23. Kobayashi K., Hernandez L.D., Galan J.E., Janeway Jr. C.A., Medzhitov R., and Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110 (2002) 191-202
24. Liew F.Y., Liu H., and Xu D. A novel negative regulator for IL-1 receptor and Toll-like receptor 4. Immunol. Lett. 96 (2005) 27-31
25. Lopez-Collazo E., Fuentes-Prior P., Arnalich F., and del Fresno C. Pathophysiology of interleukin-1 receptor-associated kinase-M: Implications in refractory state. Curr. Opin. Infect. Dis. 19 (2006) 237-244
26. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1 (2001) 135-145
27. O'Neill L.A. How Toll-like receptors signal: What we know and what we don't know. Curr. Opin. Immunol. 18 (2006) 3-9
28. Pasare C., and Medzhitov R. Toll-like receptors: Linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560 (2005) 11-18
29. Pinhal-Enfield G., Ramanathan M., Hasko G., Vogel S.N., Salzman A.L., Boons G.J., et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am. J. Pathol. 163 (2003) 711-721
30. Rehli M. Of mice and men: Species variations of Toll-like receptor expression. Trends Immunol. 23 (2002) 375-378
31. Romagne F. Current and future drugs targeting one class of innate immunity receptors: The Toll-like receptors. Drug Discov. Today 12 (2007) 80-87
32. Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171 (2003) 4304-4310
33. Sato S., Takeuchi O., Fujita T., Tomizawa H., Takeda K., and Akira S. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int. Immunol. 14 (2002) 783-791
34. Sly L.M., Rauh M.J., Kalesnikoff J., Song C.H., and Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 21 (2004) 227-239
35. Tergaonkar V. NFkappaB pathway: A good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol. 38 (2006) 1647-1653
36. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301 (2003) 640-643
37. Ziegler-Heitbrock L. The p50-homodimer mechanism in tolerance to LPS. J. Endotoxin Res. 7 (2001) 219-222